Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02651545 · ClinicalTrials.gov registry record
Effects of Teriflunomide (Aubagio) on Cognitive and Vocational Outcomes in Multiple Sclerosis
A clinical trial, sponsored by State University of New York at Buffalo.
- Completed
- Registry status
- 60
- Enrollment target
NCT02651545 is a clinical trial that has completed, run by State University of New York at Buffalo. The registered enrollment target is 60 participants.
The verdict
NCT02651545 has completed, sponsored by State University of New York at Buffalo.
- COMPLETED
- Registry status
- 60 participants
- Enrollment target
Study Summary
Cognitive impairment is common in MS and has devastating impact on functional activities. There is a great demand for medications that will enhance cognitive capacity in MS patients. The effect of teriflunomide on cognition and vocational capacity is unknown. The investigators will address these questions in a sample of 30 relapsing MS patients treated with teriflunomide. Cognitive impairment will be measured by calculating an information processing speed index and a memory composite index from conventional, validated neuropsychological tests as recommended by consensus opinion publications. Vocational performance will be monitored using a newly developed online survey called the Multiple Sclerosis Vocational Monitoring Survey (MSVMS). This study will elucidate the effect of teriflunomide on these important outcomes.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2014-02 |
| Est. Completion | 2020-11-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02651545
The ClinicalTrials.gov registry entry for NCT02651545 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is State University of New York at Buffalo, which has 243 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02651545 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02651545 about?
NCT02651545 is a clinical study titled "Effects of Teriflunomide (Aubagio) on Cognitive and Vocational Outcomes in Multiple Sclerosis". Cognitive impairment is common in MS and has devastating impact on functional activities. There is a great demand for medications that will enhance cognitive capacity in MS patients. The effect of teriflunomide on cognition and vocational capacity is unknown. The investigators will address these que...
What is the current status of trial NCT02651545?
This trial is currently completed. The enrollment target is 60 participants. The study started on 2014-02. Estimated completion is 2020-11-30.
Who is sponsoring clinical trial NCT02651545?
This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.